Led · Equity · Sep 2024

Abolis Biotechnologies, based in Évry-Courcouronnes, France, specializes in industrial solutions using microorganisms across food, healthcare, cosmetics and chemicals. The company combines expertise in biology, fermentation, IT, robotics, analytics and industrial property to develop bioproduction solutions. It leverages biotechnologies and micro-organisms to create economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients. Abolis raised €35M in funding to support its growth. Backers included L’Oréal’s venture capital fund BOLD, DeepTech & Climate Fonds, and Evonik Venture Capital as lead investors, alongside Clay Capital, ICOS Capital and Liberset. The company intends to use the funds to accelerate expansion into global markets and to speed R&D to bring its own portfolio of ingredients, to be industrialized with partners, to market. The investment was accompanied by a new strategic industrial partnership between Abolis, L’Oréal and Evonik to bring selected innovations to market for the healthcare, cosmetic and chemical sectors. The company is led by CEO Cyrille Pauthenier.

Participated · Equity · Jul 2024

Strohm designs and produces thermoplastic composite pipe (TCP) systems used across conventional and renewable energy applications. The company traces its roots to 1995 when two aerospace engineers founded Airborne International and later developed TCP for Shell in 1999. It built a full-scale TCP production site in IJmuiden (Port of Amsterdam) in 2012 and rebranded to Strohm in October 2020. Strohm supplies high-end composite products to sectors including space, aerospace and offshore energy. The company recently secured €30M in equity funding to accelerate growth, especially in hydrogen and carbon capture, utilisation and storage (CCUS) applications. Management says the funding and new partnership will help scale its technologies and support expansion in energy transformation markets. Strohm manufactures Thermoplastic Composite Pipe (TCP), an unbonded, flexible, corrosion-resistant pipe system overwrapped with aramid or glass fibres and an outer thermoplastic coating for subsea transport of hydrogen, CO2 and other gases. The company positions TCP as a lightweight, long-length reelable solution that reduces installation cost and carbon footprint versus steel and is agnostic to fluids including hydrogen, ammonia and CO2. Strohm plans to use recent funding to accelerate manufacturing operations, increase capacity and support rollout into offshore green hydrogen and CCUS markets, while helping clients meet net-zero goals. Management cites the largest orderbook in the company's history and rapidly increased global sales as drivers for an accelerated growth path. The business employs about 170 people across facilities in IJmuiden, Houston, Kuala Lumpur and Rio de Janeiro and built a full-scale TCP production site in IJmuiden in 2012. Founded in 1995, Strohm has a track record of supplying TCP into harsh offshore conditions and recently won an order to supply over 11 km of TCP for a Wilhelmshaven green gas terminal project. Strohm produces thermoplastic composite pipe (TCP) designed to transport hydrogen, CO2, ammonia and water with flexibility and resistance to corrosion and embrittlement compared with steel. The company says TCP is more affordable than steel, is 100% recyclable, and produces around 50% fewer greenhouse gas emissions during manufacture. Strohm highlights TCP can transfer up to nine times the amount of energy compared to a cable and can be used to store hydrogen, increasing offshore wind farm uptime. It operates a full-scale production site in IJmuiden (Port of Amsterdam) built in 2012, became independent in 2014, and rebranded to Strohm in October 2020. Financially, Strohm announced a €14M first close led by HydrogenOne (a €10M investment) with participation from Shell Ventures, Chevron Technology Ventures, and Evonik Venture Capital, and anticipates a further close later in 2022. The company plans to use the proceeds to expand capacity at its Dutch manufacturing facility and advance its energy-transition agenda, targeting planned offshore green hydrogen and CCUS projects in the North Sea basin.

Participated · Series B · Apr 2024

Velox, based in Kfar Saba, Israel, develops, manufactures and sells industrial-grade direct-to-shape digital decoration solutions for the rigid container industry. Its proprietary technology, based on formulated inks and a dedicated deposition architecture, introduces an entirely new approach to digital printing for packaging decoration. Velox's commercial solutions include industrial-grade digital decorators for mass production of beverage cans, tubes, and aerosol cans. The company is led by Marian Cofler (CEO) and Adrian Cofler (COO). Velox raised $38M in funding led by Fortissimo Capital with participation from existing investors including JAL Ventures, O.R.T. Technologies, Ilan Holdings, Evonik, Waypoint Investors and Migdal Insurance & Finance. The company intends to use the funds to accelerate its global presence and to innovate in high-speed, direct-to-container digital printing. Velox develops and manufactures industrial-grade direct-to-shape digital decoration solutions for the rigid container industry using its proprietary DTS-Inkjet technology. The DTS-Inkjet system is based on formulated inks and a deposition architecture designed to match or replace existing decoration technologies on quality, production speed, and total cost-of-ownership. The company positions its solution as an end-to-end replacement that also offers greater agility and efficiency versus legacy methods. Velox was co-founded by Marian Cofler (CEO) and Adrian Cofler (COO). The business completed a $32m funding round to support commercialization and scale. Velox intends to use the proceeds to expand digital printing from special editions into the mass packaging decoration market.

Participated · Equity · Sep 2023

HPNow develops on-site, autonomous systems that generate ultra-pure hydrogen peroxide for clean water and sanitation. Its solutions target agriculture, process water, and the food and beverage sectors and can help break down hazardous micro-pollutants in drinking water originating from pharmaceuticals, cosmetics, and O&G industries. Led by CEO Ziv Gottesfeld, the company was spun out of the Danish Technical University (DTU) in 2015 and operates across Europe, the Americas and Asia. The company intends to use new funding to scale marketing, sales, technical support, and production capacity to address market demand. The fundraising was reported by FinSMEs on 19/09/2023.

Participated · Series D · Mar 2023

Vivasure Medical develops advanced polymer implants and delivery systems for minimally invasive vessel closure in cardiology, interventional radiology and vascular surgery. Its lead product, PerQseal, is designed to be the first sutureless, fully absorbable synthetic implant for large-bore vessel punctures, with a low-profile patch that can be placed from inside the vessel. Clinical studies to date have shown a low complication rate and high technical success. The company operates a fully integrated R&D and ISO 13485 certified manufacturing facility. Vivasure intends to use clinical study results to support an FDA pre-market approval submission and a multinational commercial launch of the PerQseal system. The company is led by CEO Andrew Glass and is backed by a syndicate of international medtech investors and public supporters. Vivasure Medical develops fully absorbable, patch-based large-bore percutaneous vessel closure devices for transcatheter endovascular and cardiovascular procedures. Its PerQseal technology is a proprietary bioabsorbable intravascular patch that seals the vessel from the inside and restores the artery or vein without leaving collagen, metal implants, or sutures. PerQseal is the first sutureless, fully absorbable synthetic implant for large-bore arterial punctures and is available in Europe for TAVR, TEVAR and EVAR. The next-generation PerQseal+ is under clinical evaluation in Europe and the U.S. to address more complex anatomies. Vivasure is also developing PerQseal Blue for large-bore venous closure, where no sutureless options currently exist. The company operates an integrated R&D and ISO 13485 certified manufacturing facility in Galway, Ireland and is backed by international medtech investors. Vivasure has closed the first tranche of €22 million (~$23M) of a Series D that could reach €52 million (~$54M); the financing will support U.S. and European clinical development, regulatory approvals and a planned U.S. pivotal study for PerQseal+. Vivasure Medical has developed the PerQseal platform and its first product, the Vivasure Closure Device, a fully bioabsorbable, sutureless and entirely synthetic implant and delivery system to close large‑bore arteriotomies. The device is CE marked (received January 2016) and has been evaluated in clinical studies across four European countries, demonstrating 97% device technical success with no major device‑related complications and follow‑up to 12 months. It is intended for use after percutaneous transcatheter procedures including TAVR and EVAR and offers a percutaneous alternative to surgical cut‑down. The company is based in Galway, Ireland. Vivasure plans to use the new financing to support commercialization in the European Union and to execute an FDA regulatory study to pursue United States approval. The global market for large arteriotomy closure devices is projected to exceed $500 million by 2021.